Kisunla (donanemab) Letter of Medical Necessity
Kisunla (donanemab) is an anti-amyloid antibody for early Alzheimer's disease. Prior authorization is highly restrictive, requiring confirmed amyloid pathology, MRI monitoring plans, and often Coverage with Evidence Development under CMS.
FDA-Approved Indications
- ● early symptomatic Alzheimer's disease with confirmed amyloid pathology
Why Kisunla Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Amyloid pathology not confirmed by PET scan or CSF biomarkers
- 2. Disease stage too advanced (not early symptomatic)
- 3. MRI monitoring protocol not established (ARIA surveillance)
- 4. CMS National Coverage Determination restrictions (Coverage with Evidence Development)
- 5. ApoE4 genotyping not documented
What to Include in a Kisunla Letter of Medical Necessity
Document confirmed Alzheimer's diagnosis (NIA-AA criteria), amyloid-positive PET or CSF biomarkers, MMSE 20-26 or CDR 0.5-1.0, baseline MRI without significant ARIA, ApoE4 genotype, ARIA monitoring plan (MRI schedule), and enrollment in CMS-approved registry if Medicare.
Key clinical evidence to cite:
- ✓ TRAILBLAZER-ALZ 2 Phase 3 trial — 35% slowing of clinical decline
- ✓ Amyloid plaque clearance demonstrated on PET imaging
Relevant guidelines:
- 📖 AAN 2024 Anti-Amyloid Therapy Practice Guideline
- 📖 Appropriate Use Recommendations for Donanemab
Kisunla Prior Authorization Criteria
Standard criteria across major US payers for Kisunla. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Kisunla
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Kisunla Prior Authorization FAQ
Why was my Kisunla prior authorization denied?
The most common denial reasons for Kisunla are: Amyloid pathology not confirmed by PET scan or CSF biomarkers; Disease stage too advanced (not early symptomatic); MRI monitoring protocol not established (ARIA surveillance); CMS National Coverage Determination restrictions (Coverage with Evidence Development); ApoE4 genotyping not documented.
What should a Kisunla Letter of Medical Necessity include?
Document confirmed Alzheimer's diagnosis (NIA-AA criteria), amyloid-positive PET or CSF biomarkers, MMSE 20-26 or CDR 0.5-1.0, baseline MRI without significant ARIA, ApoE4 genotype, ARIA monitoring plan (MRI schedule), and enrollment in CMS-approved registry if Medicare.
Which payers cover Kisunla?
Kisunla is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicare Part B, though formulary tier and prior authorization criteria vary.